OBJECTIVES: Our objective was to determine the prognostic value of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) for death and cardiovascular events among subjects without risk factors for heart failure (HF), which we term healthy normal. BACKGROUND: Previous studies report that plasma NT-proBNP has prognostic value for cardiovascular events in the general population even in the absence of HF. It is unclear if NT-proBNP retains predictive value in healthy normal subjects. METHODS: We identified a community-based cohort of 2,042 subjects in Olmsted County, Minnesota. Subjects with symptomatic (stage C/D) HF were excluded. The remaining 1,991 subjects underwent echocardiography and NT-proBNP measurement. We further defined healthy normal (n = 703) and stage A/B HF (n = 1,288) subgroups. Healthy normal was defined as the absence of traditional clinical cardiovascular risk factors and echocardiographic structural cardiac abnormalities. Subjects were followed for death, HF, cerebrovascular accident, and myocardial infarction with median follow-up of 9.1, 8.7, 8.8, and 8.9 years, respectively. RESULTS: NT-proBNP was not predictive of death or cardiovascular events in the healthy normal subgroup. Similar to previous reports, in stage A/B HF, plasma NT-proBNP values greater than age-/sex-specific 80th percentiles were associated with increased risk of death, HF, cerebrovascular accident, and myocardial infarction (p < 0.001 for all) even after adjustment for clinical risk factors and structural cardiac abnormalities. CONCLUSIONS: These findings do not support the use of NT-proBNP as a cardiovascular biomarker in healthy normal subjects and have important implications for NT-proBNP-based strategies for early detection and primary prevention of cardiovascular disease. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: Our objective was to determine the prognostic value of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) for death and cardiovascular events among subjects without risk factors for heart failure (HF), which we term healthy normal. BACKGROUND: Previous studies report that plasma NT-proBNP has prognostic value for cardiovascular events in the general population even in the absence of HF. It is unclear if NT-proBNP retains predictive value in healthy normal subjects. METHODS: We identified a community-based cohort of 2,042 subjects in Olmsted County, Minnesota. Subjects with symptomatic (stage C/D) HF were excluded. The remaining 1,991 subjects underwent echocardiography and NT-proBNP measurement. We further defined healthy normal (n = 703) and stage A/B HF (n = 1,288) subgroups. Healthy normal was defined as the absence of traditional clinical cardiovascular risk factors and echocardiographic structural cardiac abnormalities. Subjects were followed for death, HF, cerebrovascular accident, and myocardial infarction with median follow-up of 9.1, 8.7, 8.8, and 8.9 years, respectively. RESULTS: NT-proBNP was not predictive of death or cardiovascular events in the healthy normal subgroup. Similar to previous reports, in stage A/B HF, plasma NT-proBNP values greater than age-/sex-specific 80th percentiles were associated with increased risk of death, HF, cerebrovascular accident, and myocardial infarction (p < 0.001 for all) even after adjustment for clinical risk factors and structural cardiac abnormalities. CONCLUSIONS: These findings do not support the use of NT-proBNP as a cardiovascular biomarker in healthy normal subjects and have important implications for NT-proBNP-based strategies for early detection and primary prevention of cardiovascular disease. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough Journal: N Engl J Med Date: 2002-07-18 Impact factor: 91.245
Authors: Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett Journal: J Am Coll Cardiol Date: 2002-09-04 Impact factor: 24.094
Authors: Steven J Jacobsen; Douglas W Mahoney; Margaret M Redfield; Kent R Bailey; John C Burnett; Richard J Rodeheffer Journal: Ann Epidemiol Date: 2004-09 Impact factor: 3.797
Authors: W Ray Kim; Scott W Biggins; Walter K Kremers; Russell H Wiesner; Patrick S Kamath; Joanne T Benson; Erick Edwards; Terry M Therneau Journal: N Engl J Med Date: 2008-09-04 Impact factor: 91.245
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan Journal: N Engl J Med Date: 2004-02-12 Impact factor: 91.245
Authors: Paul A Heidenreich; Matthew A Gubens; Gregg C Fonarow; Marvin A Konstam; Lynne W Stevenson; Paul G Shekelle Journal: J Am Coll Cardiol Date: 2004-03-17 Impact factor: 24.094
Authors: Allison M Pritchett; Steven J Jacobsen; Douglas W Mahoney; Richard J Rodeheffer; Kent R Bailey; Margaret M Redfield Journal: J Am Coll Cardiol Date: 2003-03-19 Impact factor: 24.094
Authors: Alain G Bertoni; Lynne E Wagenknecht; Dalane W Kitzman; Santica M Marcovina; Julia T Rushing; Mark A Espeland Journal: Obesity (Silver Spring) Date: 2011-09-29 Impact factor: 5.002
Authors: William S Bradham; Michelle J Ormseth; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein Journal: Inflammation Date: 2014-06 Impact factor: 4.092
Authors: David M Leistner; Jens Klotsche; Lars Pieper; Sylvia Palm; Günter K Stalla; Hendrik Lehnert; Sigmund Silber; Winfried März; Hans-Ulrich Wittchen; Andreas M Zeiher Journal: Clin Res Cardiol Date: 2013-01-04 Impact factor: 5.460
Authors: Eui-Young Choi; Hossein Bahrami; Colin O Wu; Philip Greenland; Mary Cushman; Lori B Daniels; Andre L C Almeida; Kihei Yoneyama; Anders Opdahl; Aditya Jain; Michael H Criqui; David Siscovick; Christine Darwin; Alan Maisel; David A Bluemke; Joao A C Lima Journal: Circ Heart Fail Date: 2012-10-02 Impact factor: 8.790